Differential effects of renin–angiotensin–aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension

CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials

(2013) Kenneth F. Schulz   ANNALS OF INTERNAL MEDICINE

Effect of aliskiren treatment on endothelium-dependent vasodilation and aortic stiffness in essential hypertensive patients

(2012) Agostino Virdis et al.   EUROPEAN HEART JOURNAL

The human sympathetic nervous system: its relevance in hypertension and heart failure

(2012) G. Parati et al.   EUROPEAN HEART JOURNAL

Adipocytes Produce Aldosterone Through Calcineurin-Dependent Signaling Pathways

(2012) Ana M. Briones et al.   HYPERTENSION

Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin–angiotensin system activity in obese hypertensive patients

(2012) Michael Boschmann et al.   JOURNAL OF HYPERTENSION

Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension

(2012) Jens Jordan et al.   JOURNAL OF HYPERTENSION

Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients

(2011) L. Siddiqi et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Mechanisms linking obesity to hypertension

(2011) J. A. N. Dorresteijn et al.   Obesity Reviews

Central Pressure and Biomarker Responses to Renin Inhibition with Hydrochlorothiazide and Ramipril in Obese Hypertensives: The ATTAIN Study

(2011) Adam Whaley-Connell et al.   CardioRenal Medicine

Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis

(2010) C. Vlachopoulos et al.   EUROPEAN HEART JOURNAL

Different Effects of Aliskiren and Losartan on Fibrinolysis and Insulin Sensitivity in Hypertensive Patients with Metabolic Syndrome

(2010) R. Fogari et al.   HORMONE AND METABOLIC RESEARCH

Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis

(2010) Yoichi Inaba et al.   INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING

Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome

(2010) W Krone et al.   JOURNAL OF HUMAN HYPERTENSION

Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy

(2009) Scott D. Solomon et al.   CIRCULATION

Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance

(2009) Sabine Perl et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial

(2009) Roland E Schmieder et al.   JOURNAL OF HYPERTENSION

Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document

(2009) Giuseppe Mancia et al.   JOURNAL OF HYPERTENSION